Project cooperation
SSO-001 for Osteoarthritis (OA)
SSO-001 may act as a disease-modifying drug and relieves OA associated symptoms, completed Phase IIa clinical study.
- Research
- Execution
- Technical
- Financing
- Sales/Distribution
SANSHO Co., Ltd. is a pharmaceutical and healthcare company based in Nihonbashi, Tokyo. Founded in 2008, the company's mission is to "contribute to the health and happiness of the world through cyclic phosphatidic acid (cPA)." They develop new drugs, primarily focusing on treatments for conditions like osteoarthritis and pulmonary fibrosis, using a synthetic derivative of cPA called 2ccPA. The company also provides natural cPA (N-cPA) as a raw material for cosmetics and food products, leveraging its benefits for skin health. The company's headquarters are in Nihonbashi, with a research lab in Tsukuba City.
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
Project cooperation
SSO-001 for Osteoarthritis (OA)
SSO-001 may act as a disease-modifying drug and relieves OA associated symptoms, completed Phase IIa clinical study.
Project cooperation
SSI-002 for Idiopathic Pulmonary Fibrosis (IPF)
SSI-002 is a promising therapeutic candidate for pulmonary fibrosis, planned Phase I clinical study in 2026.
Project cooperation
SSD-004 for Systemic Scleroderma (SSc)
SSD-004 could be a novel strategy for the treatment of SSc.
Project cooperation
SSH-005 for Hypotrichosis (congenital lack of hair)
SSH-005 has potential for use in congenital hypotrichosis.